April 28, 2017 Drug Utilization Review Board
»
Item 1 - Call to order
Item 1
Call to order
»
Item 2 - Approval of minutes from Jan. 27, 2017 (Vote required)
Item 2
Approval of minutes from Jan. 27, 2017 (Vote required)
»
Item 3 - Old business: Report on Health and Human Services Commission (HHSC) decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the Jan. 27, 2017, meeting
Item 3
Old business: Report on Health and Human Services Commission (HHSC) decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the Jan. 27, 2017, meeting
»
Item 4 (Part 1 of 2) - New business:
Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Anti-allergens, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a.pdf)
b. Antibiotics, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b.pdf)
c. Anticoagulants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c.pdf)
d. Antidepressants, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d.pdf)
e. Antidepressants, SSRIs (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e.pdf)
f. Antidepressants, tricyclic (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f.pdf)
g. Antihyperuricemics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g.pdf) h. Antiparkinson agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4h.pdf)
i. Anxiolytics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4i.pdf)
j. Beta-blockers(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4j.pdf)
k. Bile salts (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4k.pdf)
l. BPH treatments (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4l.pdf)
m. Bronchodilators, beta agonist (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4m.pdf)
n. COPD agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4n.pdf)
o. Cough and cold (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4o.pdf)
p. Erythropoiesis stimulating proteins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4p.pdf)
q. Glucocorticoids, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4q.pdf)
r. HAE treatments (/sites/hhs/flles//documents/about-hhs/communications-events/meetings-events/dur/101416-4r.pdf)
s. Hepatitis C agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4s.pdf)
t. Hypoglycemics, SGLT2 (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4t.pdf)
u. Immune globulins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4u.pdf)
v. Lincosamides / oxazolidinones / streptogramins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-
4v.pdf)
w. Lipotropics, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4w.pdf)
x. Lipotropics, statins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4x.pdf)
y. PAH Agents, oral and inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4y.pdf)
z. Pancreatic enzymes (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4z.pdf)
aa. Sedative hypnotics (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4aa.pdf)
ab. Urea cycle disorders, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4bb.pdf)
Public Comment on new drugs to be reviewed for the Medicaid PDL:
a. Alzheimer's agents / Namzaric Dose Pack (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a-PDL.pdf)
b. Hypoglycemics, Incretin Mimetics / Enhancers / Adlyxin (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b-PDL.pdf)
c. Hypoglycemics, Incretin Mimetics/ Enhancers/Soliqua (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c-PDL.pdf)
d. Hypoglycemics, Incretin Mimetics/ Enhancers/Xultophy (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d-PDL.pdf)
e. Hypoglycemics, Insulins/ Basaglar Kwikpen (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e-PDLpdf)
f. Immunomodulators, Atopic Dermatitis / Eucrisa (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f-PDLpdf)
g. Stimulants and related agents / Vyvanse chewable tablet (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g-PDL.pdf)
Item 4 (Part 1 of 2)
New business:Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Anti-allergens, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a.pdf)
b. Antibiotics, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b.pdf)
c. Anticoagulants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c.pdf)
d. Antidepressants, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d.pdf)
e. Antidepressants, SSRIs (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e.pdf)
f. Antidepressants, tricyclic (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f.pdf)
g. Antihyperuricemics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g.pdf) h. Antiparkinson agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4h.pdf)
i. Anxiolytics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4i.pdf)
j. Beta-blockers(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4j.pdf)
k. Bile salts (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4k.pdf)
l. BPH treatments (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4l.pdf)
m. Bronchodilators, beta agonist (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4m.pdf)
n. COPD agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4n.pdf)
o. Cough and cold (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4o.pdf)
p. Erythropoiesis stimulating proteins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4p.pdf)
q. Glucocorticoids, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4q.pdf)
r. HAE treatments (/sites/hhs/flles//documents/about-hhs/communications-events/meetings-events/dur/101416-4r.pdf)
s. Hepatitis C agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4s.pdf)
t. Hypoglycemics, SGLT2 (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4t.pdf)
u. Immune globulins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4u.pdf)
v. Lincosamides / oxazolidinones / streptogramins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-
4v.pdf)
w. Lipotropics, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4w.pdf)
x. Lipotropics, statins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4x.pdf)
y. PAH Agents, oral and inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4y.pdf)
z. Pancreatic enzymes (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4z.pdf)
aa. Sedative hypnotics (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4aa.pdf)
ab. Urea cycle disorders, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4bb.pdf)
Public Comment on new drugs to be reviewed for the Medicaid PDL:
a. Alzheimer's agents / Namzaric Dose Pack (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a-PDL.pdf)
b. Hypoglycemics, Incretin Mimetics / Enhancers / Adlyxin (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b-PDL.pdf)
c. Hypoglycemics, Incretin Mimetics/ Enhancers/Soliqua (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c-PDL.pdf)
d. Hypoglycemics, Incretin Mimetics/ Enhancers/Xultophy (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d-PDL.pdf)
e. Hypoglycemics, Insulins/ Basaglar Kwikpen (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e-PDLpdf)
f. Immunomodulators, Atopic Dermatitis / Eucrisa (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f-PDLpdf)
g. Stimulants and related agents / Vyvanse chewable tablet (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g-PDL.pdf)
»
Item 4 (Part 2 of 2) - New business:
Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Anti-allergens, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a.pdf)
b. Antibiotics, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b.pdf)
c. Anticoagulants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c.pdf)
d. Antidepressants, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d.pdf)
e. Antidepressants, SSRIs (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e.pdf)
f. Antidepressants, tricyclic (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f.pdf)
g. Antihyperuricemics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g.pdf) h. Antiparkinson agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4h.pdf)
i. Anxiolytics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4i.pdf)
j. Beta-blockers(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4j.pdf)
k. Bile salts (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4k.pdf)
l. BPH treatments (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4l.pdf)
m. Bronchodilators, beta agonist (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4m.pdf)
n. COPD agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4n.pdf)
o. Cough and cold (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4o.pdf)
p. Erythropoiesis stimulating proteins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4p.pdf)
q. Glucocorticoids, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4q.pdf)
r. HAE treatments (/sites/hhs/flles//documents/about-hhs/communications-events/meetings-events/dur/101416-4r.pdf)
s. Hepatitis C agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4s.pdf)
t. Hypoglycemics, SGLT2 (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4t.pdf)
u. Immune globulins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4u.pdf)
v. Lincosamides / oxazolidinones / streptogramins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-
4v.pdf)
w. Lipotropics, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4w.pdf)
x. Lipotropics, statins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4x.pdf)
y. PAH Agents, oral and inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4y.pdf)
z. Pancreatic enzymes (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4z.pdf)
aa. Sedative hypnotics (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4aa.pdf)
ab. Urea cycle disorders, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4bb.pdf)
Public Comment on new drugs to be reviewed for the Medicaid PDL:
a. Alzheimer's agents / Namzaric Dose Pack (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a-PDL.pdf)
b. Hypoglycemics, Incretin Mimetics / Enhancers / Adlyxin (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b-PDL.pdf)
c. Hypoglycemics, Incretin Mimetics/ Enhancers/Soliqua (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c-PDL.pdf)
d. Hypoglycemics, Incretin Mimetics/ Enhancers/Xultophy (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d-PDL.pdf)
e. Hypoglycemics, Insulins/ Basaglar Kwikpen (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e-PDLpdf)
f. Immunomodulators, Atopic Dermatitis / Eucrisa (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f-PDLpdf)
g. Stimulants and related agents / Vyvanse chewable tablet (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g-PDL.pdf)
Item 4 (Part 2 of 2)
New business:Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Anti-allergens, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a.pdf)
b. Antibiotics, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b.pdf)
c. Anticoagulants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c.pdf)
d. Antidepressants, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d.pdf)
e. Antidepressants, SSRIs (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e.pdf)
f. Antidepressants, tricyclic (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f.pdf)
g. Antihyperuricemics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g.pdf) h. Antiparkinson agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4h.pdf)
i. Anxiolytics(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4i.pdf)
j. Beta-blockers(/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4j.pdf)
k. Bile salts (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4k.pdf)
l. BPH treatments (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4l.pdf)
m. Bronchodilators, beta agonist (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4m.pdf)
n. COPD agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4n.pdf)
o. Cough and cold (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4o.pdf)
p. Erythropoiesis stimulating proteins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4p.pdf)
q. Glucocorticoids, inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4q.pdf)
r. HAE treatments (/sites/hhs/flles//documents/about-hhs/communications-events/meetings-events/dur/101416-4r.pdf)
s. Hepatitis C agents (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4s.pdf)
t. Hypoglycemics, SGLT2 (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4t.pdf)
u. Immune globulins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4u.pdf)
v. Lincosamides / oxazolidinones / streptogramins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-
4v.pdf)
w. Lipotropics, other (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4w.pdf)
x. Lipotropics, statins (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4x.pdf)
y. PAH Agents, oral and inhaled (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4y.pdf)
z. Pancreatic enzymes (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4z.pdf)
aa. Sedative hypnotics (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4aa.pdf)
ab. Urea cycle disorders, oral (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4bb.pdf)
Public Comment on new drugs to be reviewed for the Medicaid PDL:
a. Alzheimer's agents / Namzaric Dose Pack (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4a-PDL.pdf)
b. Hypoglycemics, Incretin Mimetics / Enhancers / Adlyxin (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4b-PDL.pdf)
c. Hypoglycemics, Incretin Mimetics/ Enhancers/Soliqua (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4c-PDL.pdf)
d. Hypoglycemics, Incretin Mimetics/ Enhancers/Xultophy (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4d-PDL.pdf)
e. Hypoglycemics, Insulins/ Basaglar Kwikpen (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4e-PDLpdf)
f. Immunomodulators, Atopic Dermatitis / Eucrisa (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4f-PDLpdf)
g. Stimulants and related agents / Vyvanse chewable tablet (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-4g-PDL.pdf)
»
Item 5 - Therapeutic and clinical drug reviews and updates - Chris Andrews, Pharm. D., Magellan Medicaid Administration
Item 5
Therapeutic and clinical drug reviews and updates - Chris Andrews, Pharm. D., Magellan Medicaid Administration
»
Item 6 - Executive work session
Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Chapter 354, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
Item 6
Executive work sessionPursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Chapter 354, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
»
Item 8 - Announcements of drugs recommended for the Medicaid PDL
Item 8
Announcements of drugs recommended for the Medicaid PDL
»
Item 9 - Retrospective DUR: Larry Dent, Pharm. D., BCPS, Xerox Heritage, LLC
a. Report on recent retrospective DUR interventions sent:
i. Gastrointestinal disorders management ii. Naloxone for opiate-related overdose
b. Report on recent retrospective DUR interventions outcome:
i. Chronic non-cancer pain
ii. Stroke prevention
iii. Attention-deficit hyperactivity disorder medication management
c. Retrospective DUR proposals: (Vote required)
i. Diabetes disease management (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-9i.pdf)
ii. Management of second generation antipsychotics in youth (/sites/hhs/files//documents/about-hhs/communications-events/meetings-
events/dur/042817-9ii.pdf)
iii. Management of psychotropic drugs in adults (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-
9iii.pdf)
Item 9
Retrospective DUR: Larry Dent, Pharm. D., BCPS, Xerox Heritage, LLCa. Report on recent retrospective DUR interventions sent:
i. Gastrointestinal disorders management ii. Naloxone for opiate-related overdose
b. Report on recent retrospective DUR interventions outcome:
i. Chronic non-cancer pain
ii. Stroke prevention
iii. Attention-deficit hyperactivity disorder medication management
c. Retrospective DUR proposals: (Vote required)
i. Diabetes disease management (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-9i.pdf)
ii. Management of second generation antipsychotics in youth (/sites/hhs/files//documents/about-hhs/communications-events/meetings-
events/dur/042817-9ii.pdf)
iii. Management of psychotropic drugs in adults (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-
9iii.pdf)
»
Item 10 - Prospective prior authorization proposals (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-10.pdf) (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (Vote required) - Growth hormone (revised)
Item 10
Prospective prior authorization proposals (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-10.pdf) (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (Vote required) - Growth hormone (revised)
»
Items 11 - 13 - 11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University ofTexas at Austin College of Pharmacy (Vote required)
a. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anticholinergic Drugs (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 a.pdf)
b. Aerosolized Agents - Metered-Dose Inhalers (MDIs): B2-Adrenergic Drugs (long-acting) (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 b.pdf)
c. Aerosolized Agents - Metered-Dose Inhalers (MDIs): B2-Adrenergic Drugs (short-acting) (/sites/hhs/files//docurnents/about-hhs/communications-events/meetings-events/dur/042817-11 c.pdf)
d. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Inhaled Anti-inflammatory Drugs: Corticosteroids (/sites/hhs/files//documents/about-hhs/comrnunications-events/meetings-events/dur/042817-11 d.pdf)
e. Antidepressants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 e.pdf)
f. Enzyme replacement therapy (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11f.pdf)
g. HMG CoA Reductase Inhibitors (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11g.pdf) h. Novel Oral Anticoagulants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 h.pdf)
12. Adjourn
13. Next meeting date: July 28, 2017
Items 11 - 13
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University ofTexas at Austin College of Pharmacy (Vote required)a. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anticholinergic Drugs (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 a.pdf)
b. Aerosolized Agents - Metered-Dose Inhalers (MDIs): B2-Adrenergic Drugs (long-acting) (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 b.pdf)
c. Aerosolized Agents - Metered-Dose Inhalers (MDIs): B2-Adrenergic Drugs (short-acting) (/sites/hhs/files//docurnents/about-hhs/communications-events/meetings-events/dur/042817-11 c.pdf)
d. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Inhaled Anti-inflammatory Drugs: Corticosteroids (/sites/hhs/files//documents/about-hhs/comrnunications-events/meetings-events/dur/042817-11 d.pdf)
e. Antidepressants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 e.pdf)
f. Enzyme replacement therapy (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11f.pdf)
g. HMG CoA Reductase Inhibitors (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11g.pdf) h. Novel Oral Anticoagulants (/sites/hhs/files//documents/about-hhs/communications-events/meetings-events/dur/042817-11 h.pdf)
12. Adjourn
13. Next meeting date: July 28, 2017
